Shares of Bristol-Myers Squibb have soared more than 27% since the start of this year, surpassing not only the S&P 500, but also its peers Eli Lilly and AstraZeneca . What have been the main drivers of this growth, and how is Bristol-Myers valued today compared to other stocks in this competitive industry? In the following segment, taken from The Motley Fool's health care show Market Checkup, health care analysts David Williamson and Max Macaluso discuss an important valuation metric that all investors should pay attention to and why Bristol-Myers trades at a premium to many of its peers.
One of the best parts of owning big pharma stocks like Bristol-Myers Squibb is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article What's Behind Bristol-Myers Squibb's High Valuation? originally appeared on Fool.com.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.